stella
Atopic DermatitisJune 2021Summary reviewed June 2026

A Daily Pill Kept Severe Eczema Clear or Nearly Clear in 47% of Adults

Researchers tested whether baricitinib, a pill that calms immune overactivity, could keep working for adults with moderate to severe eczema over 68 weeks. About half of people who responded early stayed clear or nearly clear throughout the study.

What the trial was testing

The BREEZE-AD3 enrolled 1,645 patients with atopic dermatitis. The study was sponsored by Eli Lilly and Company and tracked outcomes across the full group of patients who matched the trial's eligibility profile.

It was a large trial designed to confirm whether the treatment works well enough for wider use. Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.

What the results showed

Nearly half of patients on baricitinib stayed clear or nearly clear at 68 weeks.

JAMA dermatology · 2021 · NCT03334435

These findings — that people on 4 mg baricitinib who responded early kept their skin improvement at 68 weeks — were published in the JAMA dermatology and represent the headline result of the study.

Researchers tracked outcomes across 1,645 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.

What this means for patients

For patients with atopic dermatitis, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.

What you can do now

Baricitinib is FDA-approved for moderate to severe eczema in adults. This study showed the drug can work for over a year in people who respond to it. If you're struggling with eczema that hasn't improved with creams or other treatments, talk to your dermatologist about whether baricitinib might help.

Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.

Open atopic dermatitis trials

RecruitingPost-approval monitoring

Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis

Single center, prospective, Open label study of sleep, pruritus and circadian function pre/post 12-weeks of dupilumab treatment in children 6-17 years old

Chicago, Illinois, United States
RecruitingObservational study

Frequency of Palpebral Involvement in Adult With Atopic Dermatitis

Atopic dermatitis is a common inflammatory skin disease, resulting from genetical, immunological and environmental factors. Head and neck are among the most frequent involved areas, almost 50% in adult patients according to most publications. Palpebral involvement is also common and a source of major quality of life impairment for patients. However, the real frequency of this palpebral involvement is unknown, only estimated about 20% in few studies. The treatment of this location remains difficult, regarding to the thickness of palpebral skin and proximity of the eye. To our knowledge, no prospective studies about allergological skin tests (such as patch-tests) in atopic patients with palpebral involvement had been conducted. Finally, atopic dermatitis is frequently associated with ophthalmological diseases such as conjunctivitis, keratoconus or cataract, which belong to the minor criteria of Hanifin and Rakja classification. A better knowledge of the atopic dermatitis palpebral involvement and the associated factors seems to be needed to improve the treatment and the quality of life of patients

Lille, France +1 more